Loading organizations...
§ Private Profile · Lausanne, Switzerland
Biotech platform developing therapies to rejuvenate the immune system by targeting hematopoietic stem cells for age-related diseases.
ImmuneAGE Bio has raised $2.0M across 1 funding round.
Key people at ImmuneAGE Bio.
ImmuneAGE Bio was founded in 2022 by Sebastian Brunemeier (CEO & Founder).
ImmuneAGE Bio has raised $2.0M in total across 1 funding round.
ImmuneAGE Bio is a Swiss-US biotech platform developing therapies to rejuvenate the immune system by targeting hematopoietic stem cells (HSCs) in the bone marrow, with operations linked to Lausanne, Switzerland, and San Juan, Puerto Rico. The company's approach involves expanding and rejuvenating HSCs in vitro for reintroduction into patients through a non-invasive "immune refresh" procedure, aiming to prevent immune aging and treat multiple age-related diseases. ImmuneAGE Bio publicly launched in July 2024, having secured at least $2.0 million in initial funding, and is currently advancing its seed round to expand high-throughput screening of small molecules. Notable investors and backers include Balaji Srinivasan, Thomas Ebeling, Karl Pfleger, Diane Seimetz, and funds such as 1517 Fund and VitaDAO. The company aims to develop an outpatient procedure using autologous rejuvenated HSCs, building on foundational research. ImmuneAGE Bio was founded in 2022 by Sebastian Brunemeier.
ImmuneAGE Bio is a preclinical biotech startup developing the first drug discovery platform for immune system rejuvenation by targeting hematopoietic stem cells (HSCs) in the bone marrow.[1][2][3] Its core technologies include the StemSupply platform for over 1,000x expansion of HSCs and the AgeScreen geroscience drug discovery engine, enabling identification of molecules like lead compound IA101—a non-toxic small molecule that rejuvenates aged HSCs with superior efficacy to prior compounds.[1][2][3] The company serves an aging global population by addressing immune decline, aiming to boost resilience against pandemics, cancer, and age-related diseases through "Immune Refresh Therapy"—a potential outpatient procedure using patients' own expanded and rejuvenated HSCs.[1][4] Backed by $2M in initial funding and VitaDAO's $50K investment, ImmuneAGE shows early momentum with prestigious investors like Balaji Srinivasan and Thomas Ebeling, plus a seed round underway as of mid-2024.[2][3][4]
ImmuneAGE Bio emerged from stealth in July 2024, founded by Sebastian Brunemeier, MSc, a serial longevity entrepreneur previously co-founder and CIO at Cambrian Biopharma, founder/COO at Samsara Therapeutics, and investor at Apollo Health Ventures and Healthspan Capital.[1][3][4] The idea stemmed from Brunemeier's expertise in longevity science (Oxford, University of Amsterdam) and recognition that transplanting young bone marrow into aged mice extends lifespan by ~30%—the largest effect of any intervention—highlighting HSCs as the immune system's aging root.[3][4] Pivotal early traction came via VitaDAO funding in April 2023 for IA101 development, de-risked by analogs' human trial safety data, with scientific co-founders like Nicola Vannini (University of Lausanne) and collaborators at Oxford (Adam Wilkinson).[2][3] The team expanded with Josef Christensen, PhD (ex-McKinsey, Novo Nordisk, StemMedical) as COO, Stephan Emmrich, PhD as Director of Immunology, and Ryan Spangler as Director of Operations.[1][2][3]
ImmuneAGE rides the geroscience and longevity biotech wave, focusing solely on immune aging—the systemic driver of frailty, cancer, and pandemics vulnerability—as HSCs originate all immune cells.[1][2][4] Timing aligns with aging populations (e.g., rising over-65 demographics) and post-COVID emphasis on immune resilience, plus advances in stem cell tech de-risking therapies.[3][4] Market tailwinds include $2M seed validating preclinical proof-of-concept, VitaDAO's decentralized biofunding model accelerating discovery, and regulatory precedents from HSC analogs.[2][3] ImmuneAGE influences the ecosystem by pioneering HSC-scale screening, potentially enabling "always-available" bone marrow donors and healthier lifespans, bridging academia (Oxford/Lausanne) with pharma-scale development.[1][4]
ImmuneAGE is poised for seed-round acceleration into IND-enabling studies for IA101, targeting "Immune Refresh" as a periodic outpatient therapy to extend healthspan.[3][4] Rising geroscience investment, AI-drug discovery synergies, and regulatory nods for cellular rejuvenation (e.g., stem cell approvals) will shape its path, with potential partnerships from big pharma eyeing immune platforms.[2][3] Its influence could evolve from niche longevity pioneer to ecosystem shaper, proving immune reboot maximizes productive years—echoing its mission to reboot the immune system at its source.[1][4]
ImmuneAGE Bio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $2M Seed | — | Andreessen Horowitz, Anorak Ventures, Ground UP Ventures, Ludlow Ventures, Motier Ventures, Octopus Ventures, Pareto Holdings, Volt Capital, Austin Ogilvie, Balaji Srinivasan | Announced |
ImmuneAGE Bio was founded in 2022 by Sebastian Brunemeier (CEO & Founder).
ImmuneAGE Bio has raised $2.0M in total across 1 funding round.
ImmuneAGE Bio's investors include Andreessen Horowitz, Anorak Ventures, Ground Up Ventures, Ludlow Ventures, Motier Ventures, Octopus Ventures, Pareto Holdings, Volt Capital, Austin Ogilvie, Balaji Srinivasan.
Key people at ImmuneAGE Bio.
